Monday, January 11, 2010 2:17:45 PM
PanGenex Focuses on Developing Immune-Boosting Spirulina-Based Products
Buzz up! 0
Companies:Pangenex Corporation
Related Quotes
Symbol Price Change
PGCX.PK 0.18 -0.03
Press Release Source: PanGenex Corporation On Wednesday December 2, 2009, 9:51 am EST
CLEARWATER, Fla.--(BUSINESS WIRE)--PanGenex Corporation (Pink Sheets:PGCX - News), a global nutraceutical and dietary supplement manufacturer and marketer, announced today that the Company is actively identifying new product development opportunities that will initially focus on the immune-boosting properties of Spirulina. The Company recently entered into a licensing agreement to begin producing the highest quality, purest form of Spirulina using a state-of-the-art closed loop growing system.
With a 60% protein content, Spirulina is a fresh water algae that contains more protein than red meat and soy. Spirulina also contains high concentrations of the antioxidant beta carotene, iron, vitamin B-12, and the rare gamma-linolenic acid (GLA), an essential fatty acid for cellular health. Over the past 15 years, extensive research on Spirulina supports a growing world acceptance of the algae for use in dietary supplements. Scientists in the U.S., Japan and China have independently discovered that small amounts of Spirulina, when added to animal feed, greatly helped animals resist infections.
“Research on Spirulina continues to support the beneficial properties of this human 'superfood.' With our overuse of antibiotics, prescribed medicines are increasingly becoming ineffective. All-natural remedies and dietary supplements sales are booming despite the national recession. We believe our entry into the Spirulina market coincides with very attractive consumer healthy living trends. We are now working closely with our scientific advisors and product consultants to capitalize on the immune-boosting properties of Spirulina to develop a whole range of commercially viable products for the over-the-counter market,” said John Stanton, Chairman of PanGenex.
About PanGenex Corporation
PanGenex pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector-leading, patented or patent pending, condition-specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Many of its products contain the purest grade of nutraceutical components available anywhere without a prescription. Since 2006, PanGenex has voluntarily submitted its product labels for review by the FDA without incidence. PanGenex products are currently sold to healthcare practitioners in 20 U.S. states, Canada, Puerto Rico, Brazil and Australia, in fine retail establishments and on the Internet including: www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com.
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM